Trial · NCT04017936

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

NCT04017936, Phase 2, Completed, Virginia Commonwealth University; results first posted 2025-08-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis. Trials, record NCT04017936. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04017936

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis
NCT number: NCT04017936
Status: Completed
Phases: Phase 2
Enrollment: 17 participants, actual
Lead sponsor: Virginia Commonwealth University
Conditions: Cardiac Sarcoidosis
Interventions: Anakinra
First posted: 2019-07-12
Last updated: 2025-08-07
Results first posted: 2025-08-07

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Inflammation Marker	Baseline to 28 days	Change in c-reactive protein in participant plasma samples
Secondary	Change in Cardiac Fibrosis	Baseline to 180 days	Change in late gadolinium enhancement evident on magnetic resonance imaging (MRI) scan

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Inflammation Marker	Baseline to 28 days	Patient 5 excluded from Anakinra group outcome analysis.	mg/L	MEAN
SECONDARY	Change in Cardiac Fibrosis	Baseline to 180 days	Reported as percent change of relative enhanced late gadolinium enhancement volume (%)	percentage change	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Inflammation Marker	Anakinra	-43	Standard Deviation 36	mg/L
Change in Inflammation Marker	Standard of Care	7	Standard Deviation 41.56	mg/L
Change in Cardiac Fibrosis	Anakinra	17.7	Standard Deviation 14.7	percentage change
Change in Cardiac Fibrosis	Standard of Care	12.3	Standard Deviation 13.3	percentage change

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Anakinra	7
Overall Study	STARTED	Standard of Care	10
Overall Study	COMPLETED	Anakinra	7
Overall Study	COMPLETED	Standard of Care	10
Overall Study	NOT COMPLETED	Anakinra	0
Overall Study	NOT COMPLETED	Standard of Care	0

Source ClinicalTrials.gov

Adverse events28

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Serious Infection	Infections and infestations	Anakinra	1	7	1
other	Serious Infection	Infections and infestations	Standard of Care	1	10	1
other	Injection site reaction	Skin and subcutaneous tissue disorders	Anakinra	3	7	3
other	Injection site reaction	Skin and subcutaneous tissue disorders	Standard of Care	3	10	3
other	Bronchitis	Infections and infestations	Anakinra	2	7	2
other	Bronchitis	Infections and infestations	Standard of Care	0	10	0
other	Atrial Fibrillation	Cardiac disorders	Anakinra	1	7	1
other	Atrial Fibrillation	Cardiac disorders	Standard of Care	0	10	0
other	Recurrent atrial tachycardia	Cardiac disorders	Anakinra	1	7	1
other	Recurrent atrial tachycardia	Cardiac disorders	Standard of Care	0	10	0

1 to 10 of 28Source ClinicalTrials.gov

See all 28 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Anakinra	0	7
Total, all-cause mortality	Standard of Care	0	10
Total, other adverse events	Anakinra	7	7
Total, other adverse events	Standard of Care	9	10
Total, serious adverse events	Anakinra	1	7
Total, serious adverse events	Standard of Care	0	10

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
34749739	DERIVED	PubMed
37092332	RESULT	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R21TR003103	Feasibility and Safety of Interleukin-1 Blockade to Treat Cardiac Sarcoidosis	KRON, JORDANA; ABBATE, ANTONIO	VIRGINIA COMMONWEALTH UNIVERSITY	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	2020 to 2021

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Anakinra vs Standard of Care: deaths from any cause	Trial comparisons
Anakinra vs Standard of Care: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04017936

GET https://conductscience.org/api/trials/v1/NCT04017936/events?page=2

API reference For AI assistants